Product Images Eliquis

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 10 images provide visual information about the product associated with Eliquis NDC 55154-0613 by Cardinal Health 107, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Apixaban Chemical Structure - apixaban struct

Apixaban Chemical Structure - apixaban struct

d9f4bccb df6a 43d3 ad27 f9d0682f054c 00

d9f4bccb df6a 43d3 ad27 f9d0682f054c 00

d9f4bccb df6a 43d3 ad27 f9d0682f054c 01

d9f4bccb df6a 43d3 ad27 f9d0682f054c 01

d9f4bccb df6a 43d3 ad27 f9d0682f054c 02

d9f4bccb df6a 43d3 ad27 f9d0682f054c 02

ELIQUIS (apixaban) tablets, 2.5mg strength, are available in a bottle of 4140 tablets. The tablets should be kept out of reach of children. No further information is available as the given text contains errors.*

d9f4bccb df6a 43d3 ad27 f9d0682f054c 03

d9f4bccb df6a 43d3 ad27 f9d0682f054c 03

This is a description of Eliquis Tablets with 2.5 mg of Apixaban in each of the 10 tablets contained within the package. It advises that the full dosage information, prescribing information, precautions and warnings can be found in the product insert. It has specific storage recommendations between 20°C and 25°C with allowances for excursions between 15°C and 30°C. The package also contains a warning that it is not child resistant and intended for institutional use only. It is recommended to be kept out of reach of children in child-resistant containers if dispensed for outpatient use. The package should not be used if any printed blister units are opened or torn. The product is marketed in the United States by Bristol-Myers Squibb Company in New Jersey and Pfizer Inc in New York. The product is distributed by Cardinal Health in Dublin, Ohio.*

ARISTOTLE Forest Plot - eliquis clin forest fig5

ARISTOTLE Forest Plot - eliquis clin forest fig5

ARISTOTLE Major Bleeding Forest Plot - eliquis forest fig1

ARISTOTLE Major Bleeding Forest Plot - eliquis forest fig1

This is a table of results obtained from a study comparing the efficacy of Apixaban and Warfarin as treatments for preventing strokes in patients with Atrial Fibrillation. The table indicates the number of events, patients per year, and the Hazard Ratio for each subgroup of patients. The subgroups are classified according to several factors such as age, gender, weight, diabetes mellitus, and other parameters. The results show that Apixaban performed better than Warfarin in most cases.*

ARISTOTLE Kaplan-Meier Curve - eliquis km fig4

ARISTOTLE Kaplan-Meier Curve - eliquis km fig4

Effect of Coadministered Drugs on Pharmacokinetics of Apixaban - eliquis pkplot drugs fig2

Effect of Coadministered Drugs on Pharmacokinetics of Apixaban - eliquis pkplot drugs fig2

This appears to be a table showing the effect of various drug interactions on the PK Fold Change and 90% confidence interval, specifically looking at combined P-gp and strong CYP3A4 inhibitors, other CYP3A4 and P-gp inhibitors, and combined P-gp and strong CYP3A4 inducers. The table lists the drug names and dosages and indicates the observed changes in AUC relative to a reference measurement. There are also some numerical values listed that appear to be indicating the degree of change observed in the study.*

O:\E-Submissions\PBO\PRODUCTS\Eliquis 202155\08. PAS ESRD Dosing\01. Orig Submission\Source\eliquis-pkplot-pop-fig3.jpg - eliquis pkplot pop fig3

O:\E-Submissions\PBO\PRODUCTS\Eliquis 202155\08. PAS ESRD Dosing\01. Orig Submission\Source\eliquis-pkplot-pop-fig3.jpg - eliquis pkplot pop fig3

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.